Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, Seattle, Washington.
Department of Pediatrics, University of Washington School of Medicine, Seattle.
JAMA Netw Open. 2021 Jan 4;4(1):e2032106. doi: 10.1001/jamanetworkopen.2020.32106.
It remains poorly understood how parents decide whether to enroll a child in a neonatal clinical trial. This is particularly true for parents from racial or ethnic minority populations. Understanding factors associated with enrollment decisions may improve recruitment processes for families, increase enrollment rates, and decrease disparities in research participation.
To assess differences in parental factors between parents who enrolled their infant and those who declined enrollment for a neonatal randomized clinical trial.
DESIGN, SETTING, AND PARTICIPANTS: This survey study conducted from July 2017 to October 2019 in 12 US level 3 and 4 neonatal intensive care units included parents of infants who enrolled in the High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) trial or who were eligible but declined enrollment. Data were analyzed October 2019 through July 2020.
Parental choice of enrollment in neonatal clinical trial.
Percentages and odds ratios (ORs) of parent participation as categorized by demographic characteristics, self-assessment of child's medical condition, study comprehension, and trust in medical researchers. Survey questions were based on the hypothesis that parents who enrolled their infant in HEAL differ from those who declined enrollment across 4 categories: (1) infant characteristics and parental demographic characteristics, (2) perception of infant's illness, (3) study comprehension, and (4) trust in clinicians and researchers.
Of a total 387 eligible parents, 269 (69.5%) completed the survey and were included in analysis. This included 183 of 242 (75.6%) of HEAL-enrolled and 86 of 145 (59.3%) of HEAL-declined parents. Parents who enrolled their infant had lower rates of Medicaid participation (74 [41.1%] vs 47 [55.3%]; P = .04) and higher rates of annual income greater than $55 000 (94 [52.8%] vs 30 [37.5%]; P = .03) compared with those who declined. Black parents had lower enrollment rates compared with White parents (OR, 0.35; 95% CI, 0.17-0.73). Parents who reported their infant's medical condition as more serious had higher enrollment rates (OR, 5.7; 95% CI, 2.0-16.3). Parents who enrolled their infant reported higher trust in medical researchers compared with parents who declined (mean [SD] difference, 5.3 [0.3-10.3]). There was no association between study comprehension and enrollment.
In this study, the following factors were associated with neonatal clinical trial enrollment: demographic characteristics (ie, race/ethnicity, Medicaid status, and reported income), perception of illness, and trust in medical researchers. Future work to confirm these findings and explore the reasons behind them may lead to strategies for better engaging underrepresented groups in neonatal clinical research to reduce enrollment disparities.
父母决定是否让孩子参加新生儿临床试验的方式仍未得到充分理解。对于来自少数族裔的父母来说,这一点尤其如此。了解与入组决策相关的因素可能会改善家庭的招募流程,提高入组率,并减少研究参与方面的差异。
评估在参加和不参加新生儿随机临床试验的父母中,父母因素的差异。
设计、地点和参与者:这项调查研究于 2017 年 7 月至 2019 年 10 月在 12 家美国 3 级和 4 级新生儿重症监护病房进行,纳入了参加高剂量促红细胞生成素治疗窒息和脑病(HEAL)试验或符合条件但拒绝入组的婴儿的父母。数据于 2019 年 10 月至 2020 年 7 月进行分析。
父母对新生儿临床试验的入组选择。
根据人口统计学特征、对孩子病情的自我评估、研究理解和对医学研究人员的信任,将父母参与的百分比和优势比(OR)进行分类。调查问题基于这样一个假设,即与拒绝入组的父母相比,选择让孩子参加 HEAL 试验的父母在以下 4 个方面存在差异:(1)婴儿特征和父母的人口统计学特征,(2)对婴儿疾病的认识,(3)对研究的理解,以及(4)对临床医生和研究人员的信任。
在 387 名符合条件的父母中,共有 269 名(69.5%)完成了调查并纳入分析。这包括 242 名 HEAL 入组者中的 183 名(75.6%)和 145 名 HEAL 拒绝者中的 86 名(59.3%)。与拒绝者相比,让孩子入组的父母参加医疗补助计划的比例较低(74 [41.1%] vs 47 [55.3%];P=0.04),年收入超过 55000 美元的比例较高(94 [52.8%] vs 30 [37.5%];P=0.03)。与白人父母相比,黑人父母的入组率较低(OR,0.35;95%CI,0.17-0.73)。报告孩子病情更严重的父母入组率更高(OR,5.7;95%CI,2.0-16.3)。与拒绝入组的父母相比,让孩子入组的父母对医学研究人员的信任度更高(平均[标准差]差异,5.3[0.3-10.3])。研究理解与入组之间没有关联。
在这项研究中,以下因素与新生儿临床试验的入组相关:人口统计学特征(即种族/民族、医疗补助状况和报告收入)、对疾病的认识以及对医学研究人员的信任。未来的工作需要进一步证实这些发现,并探讨其背后的原因,这可能会为更好地让代表性不足的群体参与新生儿临床研究提供策略,以减少入组方面的差异。